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In recent years, Candida species other than
C. albicans have emerged as causes of human
candidiasis, particularly in HIV-infected and
other immunocompromised persons (1).
C. dubliniensis, a recently described species
closely related to C. albicans (2), has been
implicated as an agent of oral candidiasis in HIV-
positive persons (2-5) but has also been recovered
from HIV-negative persons with clinical signs of
oral candidiasis and from the genital tract of
some women with vaginitis (2,4). First isolated
from AIDS patients in Dublin, Ireland (2),
C. dubliniensis has a worldwide distribution
(3-6). Most isolates are susceptible to amphoteri-
cin B and the azoles, but resistance has been
shown in HIV-positive patients on fluconazole
for oral candidiasis (7). Its potential to cause deep
or disseminated candidiasis is not known,
largely because C. dubliniensis has rarely been
isolated from sterile body sites (6); however, the
phenotypic characteristics the organism shares
with  C. albicans (producing germ tubes and
chlamydospores) suggest that some C. dublin-
iensis isolates may have been misidentified as
C. albicans.
Three cases of C. dubliniensis fungemia have
been reported from Europe, all in HIV-negative
bone marrow transplant recipients with chemo-
therapy-induced neutropenia (8). We report the
first isolation of C. dubliniensis from the blood
cultures of four patients from the United States.
All four patients had multiple underlying
conditions and at least one symptom of
septicemia (fever, hypotension, or multiple
organ system failure) at the time blood cultures
were drawn. These cultures were collected from
October 1998 to January 1999 through active,
population-based laboratory surveillance for
candidemia in residents of Connecticut and of
Baltimore City or County, Maryland (combined
population, 4.8 million). An incident case of
candidemia was defined by the first isolation of
any Candida species from a blood culture from a
resident of one of the surveillance areas. Medical
records were reviewed to obtain demographic
data, clinical data on underlying medical
conditions, treatment, and outcome.
Case 1
A 74-year-old black man from Baltimore,
with a history of chronic lymphocytic leukemia,
chronic obstructive pulmonary disease, coronary
artery disease and hypertension, was hospital-
ized for fatigue and anemia 4 weeks after
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We report the first four North American cases of Candida dubliniensis fungemia,
including the first isolation of this organism from the bloodstream of an HIV-infected
person. All isolates were susceptible in vitro to commonly used antifungal drugs. This
report demonstrates that C. dubliniensis can cause bloodstream infection; however, the
incidence of disease is not known.
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chemotherapy with chlorambucil. He received
multiple blood transfusions on day 1 of
hospitalization and quickly progressed to
multiple organ failure, including renal failure
and hepatic and cardiogenic shock, and was
transferred to a medical intensive care unit.
Multiple indwelling catheters were placed. A
peripheral blood culture obtained 3 days after
admission grew C. dubliniensis. The patient died
1 day after this single positive blood culture was
drawn. No autopsy was performed.
Case 2
A 30-year-old black woman from Connecticut
with a history of end-stage liver disease was
hospitalized for gastrointestinal bleeding and
refractory ascites. The patient had a history of
intravenous drug use and alcoholism but was not
infected with HIV. During hospitalization, she
required multiple transfusions; acute renal
failure requiring hemodialysis followed. The
patient was receiving many medications,
including vasopressors, antibiotics, and corticos-
teroids. Yeasts were isolated from peripheral
blood cultures collected on days 11, 15, and 17 of
hospitalization; four of the isolates were later
identified as C. dubliniensis. The patient had a
triple-lumen catheter placed on the day before
the initial isolation of the organism. She was
treated with intravenous fluconazole 200 mg/day
for 5 days, starting 6 days after the first yeast
isolation. A blood culture collected on day 20 was
negative, and the patient died after 24 days of
hospitalization. No autopsy was performed.
Case 3
The third patient was a 39-year-old black
man from Baltimore who was admitted for
complications of end-stage liver disease, includ-
ing acute renal failure and ascites, and diffuse
lymphadenopathy of unknown etiology. He also
had a history of diabetes mellitus. A week before
hospitalization, the patient had been discharged
from another hospital, where he had been
admitted because of pancreatitis and treated for
Escherichia coli bacteremia and renal insuffi-
ciency. The patient had a peripheral intravenous
catheter and a central venous catheter placed
during this hospitalization. On day 2, yeasts
were recovered from a peripheral blood culture;
these were later identified as C. dubliniensis. By
the time the result of the blood culture was
reported, the patient’s clinical status had
deteriorated because of worsening respiratory
distress. He was treated with fluconazole 400
mg/day for 3 days but died 5 days after the blood
culture was obtained. No autopsy was per-
formed.
Case 4
The fourth case occurred in a 37-year-old
white woman from Baltimore, who had a history
of intravenous drug use, chronic deep vein
thrombosis, and valvular heart disease. She was
also HIV-infected (CD4+ lymphocyte count was
779 cells/ml). She was hospitalized because of
fever and chills, and blood cultures on day 1 of
admission grew group A streptococci, for which
she was treated with various antibiotics. On day
7, fever developed and peripheral blood cultures
grew C. dubliniensis and C. glabrata. She was
treated with oral fluconazole 400 mg/day for 2
weeks and was discharged to a skilled-nursing
facility 1 day after being started on fluconazole.
Microbiologic Results
All seven isolates were originally identified
as C. albicans on the basis of their phenotypic
characteristics. They were reexamined at the
Fungus Reference Laboratory, Centers for
Disease Control and Prevention, and reidenti-
fied as C. dubliniensis on the basis of biochemical
and morphologic criteria (9). The identification
was confirmed by reactivity of DNA with a
polymerase chain reaction (PCR)-enzyme immu-
noassay (EIA) probe specific for this species (10)
and by PCR amplification of a region containing
the novel C. dubliniensis group I intron in the
large ribosomal subunit (11).
Broth microdilution MICs were determined
according to National Committee for Clinical
Laboratory Standards document M27-A guide-
lines (12). All isolates were susceptible to
commonly used antifungal agents. MICs of
amphotericin B were 0.25 (one patient) to
0.5 µg/ml (three patients); MICs of itraconazole
were from <0.015 (two patients) to 0.03 µg/ml
(two patients): and MICs of fluconazole and
flucytosine were <0.125 µg/ml for all isolates.
Conclusions
The incidence of candidemia due to
C. dubliniensis is not known, largely because of
the difficulty in readily distinguishing this
species from the morphologically similar
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surveillance conducted in 1992-93 in two sites in
the United States (population 5.8 million), we did
not find C. dubliniensis as an agent of
candidemia, even with the DNA-based identifi-
cation method used in this study (13). More
recently, three cases of C. dubliniensis fungemia
have been reported from Europe in patients with
chemotherapy-induced immunosuppression and
bone marrow transplantation (8). The four cases
described here are the first reported in the
United States.
The demonstration that C. dubliniensis has
the potential to cause bloodstream infection
provides information central to our understand-
ing of its clinical relevance and pathogenic
potential. As in the earlier European report (8),
the patients in our study had multiple serious
medical conditions. Two of the four patients had
end-stage liver disease, which is a known risk
factor for bloodstream infections with organisms
that are part of the normal gastrointestinal flora
because of breakdown of the normal mucosal
barrier (14). This strongly suggests that the
gastrointestinal tract was the source of the
C. dubliniensis in these patients. Odds et al. (6)
have reported the reidentification as
C. dubliniensis of a number of C. albicans
isolates that were obtained from fecal surveil-
lance cultures in hematologic patients.
The isolation of C. dubliniensis from mucosal
sites in HIV-infected persons has been widely
reported (3,5). Although not severely
immunocompromised, our fourth patient was
HIV-positive, which makes hers the first
reported case of bloodstream infection with this
organism in an HIV-infected person. The fact
that C. dubliniensis is able to cause invasive
disease in these patients is of clinical interest.
However, it may be more significant that
C. glabrata, a recognized pathogen, was also
isolated from blood cultures in our patient.
As our population-based surveillance for
candidemia continues, we will be able to estimate
more accurately the incidence of candidemia due
to  C. dubliniensis and define more clearly its
clinical importance, epidemiologic characteris-
tics, and outcome. The specific proportional
impact of C. dubliniensis candidemia on outcome
is difficult to assess in these patients, all of whom
had multiple underlying conditions. The organ-
isms isolated from our patients were all fully
susceptible to amphotericin B, flucytosine,
fluconazole, and itraconazole. However, resis-
tance has been shown to occur in HIV-positive
patients given fluconazole treatment for oral
infection with C. dubliniensis (7). As our
knowledge about this emerging pathogenic yeast
increases and diagnostic tests are developed,
prevention and better management of the
disease will become possible.
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